# A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

> **NCT06219356** · PHASE1 · RECRUITING · sponsor: **Hangzhou GluBio Pharmaceutical Co., Ltd.** · enrollment: 110 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** GLB-002

## Key facts

- **NCT ID:** NCT06219356
- **Lead sponsor:** Hangzhou GluBio Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-11
- **Primary completion:** 2026-01-31
- **Final completion:** 2027-02-28
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06219356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06219356, "A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06219356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*